This article is more than 5 years old. Information may no longer be current.

VIDEO: Alimera's CEO views sustained therapies as path forward

Issue: October 2016

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

CHICAGO — Dan Myers, CEO of Alimera Sciences, talks about the work being done in sustained release treatment for neovascular age-related macular degeneration and diabetic macular edema, as well as other retina diseases. Alimera's sustained release fluocinolone acetonide implant Iluvien has the potential to reduce patient burden of treatment compared with anti-VEGFs, which puts Alimera "on the right side of the issue as it relates to how we treat retina disease going forward," Myers said.